CE
Therapeutic Areas
Skye Bioscience Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Nimacimab | Obesity (combination therapy) | Phase 2 |
| CB1 Receptor Inhibitor(s) | Obesity / Metabolic Diseases | R&D |
| Drug | Indication | Phase |
|---|---|---|
| Nimacimab | Obesity (combination therapy) | Phase 2 |
| CB1 Receptor Inhibitor(s) | Obesity / Metabolic Diseases | R&D |